Repligen Corp last reported quarterly results on Oct 27, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $209.3 million (+10.9% year over year) and diluted EPS of -$0.68. It usually reports 22–55 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 23, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 24, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 22–55 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 27, 2026
27 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
209
+10.9%
|
-38
-357.7%
|
-0.68
-361.5%
|
|
Jul 22, 2026
22 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
204
+11.9%
|
5
-66.3%
|
0.09
-65.4%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
194
+14.8%
|
8
+42.9%
|
0.15
+50.0%
|
|
Feb 24, 2026
55 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
198
+18.1%
|
13
+139.2%
|
-0.08
+100.0%
|
|
Oct 28, 2025
28 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
189
+21.9%
|
15
+2380.0%
|
0.26
+2700.0%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
182
+14.8%
|
15
+160.2%
|
0.26
+160.0%
|
|
Apr 29, 2025
29 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
169
+10.4%
|
6
+76.9%
|
0.10
+66.7%
|
|
Feb 20, 2025
51 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
168
+0.6%
|
-34
-105.9%
|
-617.87
-105.6%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGEN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 730272
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.